Geoff has researched monoclonal antibodies since 1980. He was part of the team that developed the first humanized antibody (Campath-1H) and worked for 25 years at the Universities of Cambridge and Oxford to develop and manufacture antibodies for clinical trials. In 2002 Geoff founded BioAnaLab, a service laboratory specialising in the analysis of biologics. In 2009 the company was acquired by Millipore and Geoff continued as Chief Scientist until 2011.
Since then he has founded several other life science businesses and worked as a freelance scientist, consultant and company director, with interests in the development of antibodies and antigens for research, diagnosis and therapy.
Ian has an outstanding scientific background in the engineering and development of therapeutic antibodies. During a UCB-Celltech sponsored PhD at the University of Leicester, Ian solved the first NMR structure of a human antibody fragment (scFv). From there he moved to MedImmune, the biologics arm of AstraZeneca. He worked on a number of antibody and non-antibody early stage therapeutic research projects covering technology validation, drug discovery and optimization. Ian is currently the CSO of Absolute Antibody, and developed many of the processes that underpin its recombinant antibody services. Ian's insights into antibody structure and engineering led to the invention of QumAb, mAbsolve's lead technology for elimination of the binding of antibodies to Fc-gamma receptors.
Nick is an entrepreneur with a background in immunology and proteomics, whose first startup Everest Biotech Ltd made 5000 traditional antibodies for the research market. He studied Biochemistry at the University of Oxford followed by a doctorate at the Sir William Dunn School of Pathology, supervised by Prof Neil Barclay. Nick is the founder and Chief Executive Officer of Absolute Antibody, a company which has pioneered the development and supply of recombinant antibodies for research and diagnosis, as well as providing protein engineering services for therapeutic products.
Our Founders and Scientific Advisors
Emeritus EP Abraham Professor of Chemical Pathology at University of Oxford. Neil's research at the Sir William Dunn School of Pathology at the University of Oxford centred on immunology and in particular the surfaces of white blood cells and how proteins at their surfaces interact and carry out their functions. From the 1980's he was greatly involved in the production of antibodies and making them widely available to the research community through his involvement with Serotec, Everest Biotech and now as Chair of the Board of Directors of Absolute Antibody
Herman Waldmann FRS
Emeritus Professor of Pathology at the University of Oxford and Head of Department from 1994-2013, Herman is an internationally-renowned immunologist and pioneer of monoclonal antibody therapy. He was responsible for development of the first humanised antibody, Campath, which is now widely used for treatment of multiple sclerosis. His research into immunological tolerance led to the first demonstrations of transplantation tolerance resulting from short-term antibody blockade.
Mike is a biochemist and immunologist with over 40 years experience of working with antibodies since his PhD under César Milstein. He joined Herman Waldmann’s team to work on therapeutic antibodies for immunosuppression where he was one of the inventors of the first humanized antibody Campath and developed an early Fc-silenced anti-CD3 antibody, otelixizumab. Mike's subsequent research at Cambridge University focused on selection and modification of antibody Fc regions. His many antibody patents and inventions have been widely licensed and he has acted as adviser to numerous biotechnology companies.
Mike studied Biochemistry before obtained his doctoral degree at the Sir William Dunn School of Pathology, University of Oxford. With a background in both wet-lab and bioinformatic methods, Mike is always keen to explore new antibody licensing, product development and service opportunities to help customers and business partners harness the benefits of antibody technology. As Vice-President of Product Portfolio and Innovation at Absolute Antibody, he has been responsible for bringing more than 7000 recombinant antibody products to market.
Former Professor of Cellular Immunology at the Sir William Dunn School of Pathology, University of Oxford, Steven's research focused on how monoclonal antibodies can be used to manipulate the immune system. He was responsible for the first demonstrations of tolerance using CD4 monoclonal antibodies and as a member of the Waldmann group was actively involved in the development of Campath antibodies. He also developed statistical methods for the analysis of antibody clusters as used in the early CD antigen workshops.
Steve was a founder of TolerRx and BioAnaLab. He has published more than 250 articles and patents on the therapeutic applications of monoclonal antibodies and the mechanisms of transplantation tolerance.
Tim has over 35 years’ experience in the life science sector. He is an accomplished commercial leader and biotechnology consultant and has extensive experience of executive level leadership within the Antibody market. He has also been CEO of the antibody manufacturer Serotec (now part of Bio-Rad) which he co-managed for 25 years.
Tim has considerable experience in all aspects of business planning and sales and marketing and is the CEO of the private biotech consulting company Pivotal Scientific Ltd and co-founder of 2B Scientific Ltd supplying Immunological Reagents to the UK life science market. Tim also founded the US custom antibody company Abcore Inc and has been a Board member of several additional companies, including Innova Biosciences Ltd, Everest Biotech Ltd, Medix Biochemica and Chromocyte Ltd.